Lumos Diagnostics Holdings Management
Management criteria checks 2/4
Lumos Diagnostics Holdings' CEO is Doug Ward, appointed in Jun 2022, has a tenure of 1.92 years. total yearly compensation is $773.94K, comprised of 62.7% salary and 37.3% bonuses, including company stock and options. directly owns 0.43% of the company’s shares, worth A$96.54K. The average tenure of the management team and the board of directors is 3.4 years and 4.5 years respectively.
Key information
Doug Ward
Chief executive officer
US$773.9k
Total compensation
| CEO salary percentage | 62.67% |
| CEO tenure | 3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.4yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Lumos Diagnostics Holdings Limited (ASX:LDX) Shares Fly 29% But Investors Aren't Buying For Growth
May 09
Lacklustre Performance Is Driving Lumos Diagnostics Holdings Limited's (ASX:LDX) 29% Price Drop
Mar 07Lumos Diagnostics Holdings Limited's (ASX:LDX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jan 20Lumos Diagnostics Holdings Limited (ASX:LDX) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Nov 28Lumos Diagnostics Holdings Limited (ASX:LDX) Stock Catapults 35% Though Its Price And Business Still Lag The Industry
Oct 14There Is A Reason Lumos Diagnostics Holdings Limited's (ASX:LDX) Price Is Undemanding
Aug 29Take Care Before Diving Into The Deep End On Lumos Diagnostics Holdings Limited (ASX:LDX)
Jan 03The Market Lifts Lumos Diagnostics Holdings Limited (ASX:LDX) Shares 387% But It Can Do More
Jul 04Bearish: Analysts Just Cut Their Lumos Diagnostics Holdings Limited (ASX:LDX) Revenue and EPS estimates
Jul 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | -US$5m |
| Sep 30 2024 | n/a | n/a | -US$7m |
| Jun 30 2024 | US$774k | US$485k | -US$9m |
| Mar 31 2024 | n/a | n/a | -US$9m |
| Dec 31 2023 | n/a | n/a | -US$9m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | US$665k | US$415k | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$25m |
| Dec 31 2022 | n/a | n/a | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$43m |
| Jun 30 2022 | US$472k | US$14k | -US$46m |
Compensation vs Market: Doug's total compensation ($USD773.94K) is above average for companies of similar size in the Australian market ($USD294.58K).
Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.
CEO
Doug Ward
Mr. Douglas Ward, also known as Doug, serves as Chief Executive Officer of Lumos Diagnostics Holdings Limited since June 20, 2022 and its Managing Director and Director since July 13, 2023. He was Chief Ex...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 3yrs | US$773.94k | 0.43% A$ 96.5k | |
| Chief Financial Officer | 3.3yrs | US$385.34k | no data | |
| Chief Technology Officer | no data | no data | no data | |
| Senior Director of Human Resources | 4.5yrs | no data | no data | |
| Senior Vice President of Commercial Operations | 3.4yrs | no data | no data | |
| Company Secretary | no data | no data | no data |
Experienced Management: LDX's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 1.9yrs | US$773.94k | 0.43% A$ 96.5k | |
| Independent Deputy Chairman of the Board | 4.6yrs | US$82.00k | 0.011% A$ 2.4k | |
| Non-Executive Chairman | 6.4yrs | US$182.78k | 0.18% A$ 41.0k | |
| Independent Director | 4.6yrs | US$65.51k | 0.023% A$ 5.2k | |
| Independent Director | 4.5yrs | US$61.88k | 0.28% A$ 62.2k | |
| Strategic Healthcare Adviser & Member of Medical Advisory Board | 3.8yrs | no data | no data |
Experienced Board: LDX's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/13 14:17 |
| End of Day Share Price | 2025/06/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lumos Diagnostics Holdings Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chris Kallos | MST Financial Services Pty Limited |